Cellebrite (CLBT) Management Meeting: The Road Ahead
Cellebrite converts more than 110% of EBITDA into free cash flow and trades at 12.5 times free cash flow, with management targeting 15% or…
NASDAQ
CLBT
8 stories
$3B Market cap · 2026-10-23
Cellebrite converts more than 110% of EBITDA into free cash flow and trades at 12.5 times free cash flow, with management targeting 15% or…
Sleep Well Portfolio’s August gains were led by Veeva, CrowdStrike and cybersecurity, while Cellebrite and WiseTech reported early AI…
$CLBT - You can make a pretty compelling case that the guidance cut was to kitchen sink the expectations for the new CEO so he has a bottom base to build off of. From the call 4-5 major deals slipped out a quarter, and Genesis isn't ramping as fast as originally thought, but new products are growing +25% & they have tailwinds in terms of FedRamp & YoY US federal basically didn't grow last year. Next quarter they beat, and re-raise guidance and stock is back to $16. 50% return from here in a quarter. Clearly if they can't close deals in Q3 at a faster pace then the recovery takes longer, but seems like good risk-reward here. Full disclosure: I added some at $10.5
Cellebrite cut 2026 ARR guidance by $15 million, replaced its CEO and saw shares fall 30% as elongated sales cycles raise execution…
$CLBT short? i don't totally get it https://t.co/6hqkVNkIss
Sleep Well Portfolio is selling SPS Commerce as AI-vulnerable and adding Veeva, Mercado Libre, Cellebrite and Sea, citing proprietary data,…
The Voss Q4 2025 Letter to Partners is up. Updates on $PAR, $FLYW, $CLBT, and new core idea $CHH, an asset light hotel franchisor that has rarely ever been cheaper. https://t.co/DTOoXGIN0M https://t.co/gjWBSHET4j
Here is a link to our Q3 2025 letter to Partners. Theme: Escaping value purgatory. https://t.co/ZSdzeu3Plg $FIVN $XPOF $EEFT $PRKS $CLBT $FLYW @jonrice80 @taylor_hndrson @Scott_K_Rodgers @AggieCapitalist https://t.co/523nEw39yJ
Letters that discuss CLBT.
Companies the stories above are also about, besides CLBT.